加速结核病新疫苗研发:全球路线图五年进展
2021年全球结核病疫苗研发路线图提出加速开发有效可负担新疫苗的行动。此后研发管线多样化,多个候选疫苗进入3期临床试验,许多中低收入国家在监管审批预期方面取得进展,但活跃临床试验候选数少、产品开发挑战持续,投资风险高且不足。
要点
- 多个结核候选疫苗已进入3期临床试验,管线较前多样化。
- 活跃临床试验候选数量仍少,产品开发挑战持续存在。
- 投资风险高且不足,需扩大资助方并加强多利益相关方协调。
核心结论
- 结核疫苗研发路线图实施五年取得管线多样化和3期试验进展,但活跃试验候选少、投资不足且风险高,需加强协调与投入。
研究设计与样本
- 本文为对2021年全球结核病疫苗研发路线图实施五年进展的总结性报告。
主要发现
- 自2021年以来研发管线多样化,多个候选疫苗处于3期临床试验。
- 许多中低收入国家在预期监管审批方面取得重要进展。
- 活跃临床试验候选数量少,产品开发挑战持续存在。
- 与疫苗制造商接触增加,但受需求不明确和采购承诺不足制约。
- 结核疫苗研发投资仍风险高且不充足,需识别和规划成本效益实施并减少犹豫与污名。
临床怎么用
- 关注进入3期临床试验的结核候选疫苗进展,为未来监管审批和接种实施做准备。
- 在疫苗上市前规划成本效益实施策略,并针对犹豫和污名开展应对。
局限性
- 原文未报告具体候选疫苗数量、试验样本量、疗效数值或投资金额。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2021, a global tuberculosis vaccine research and development roadmap proposed a series of actions to accelerate the development of new, effective, and affordable vaccines that are urgently needed to eliminate tuberculosis globally. Since then, the pipeline has diversified, several candidates are currently in phase 3 clinical trials, and many low-income and middle-income countries have made important steps in anticipating regulatory approval. However, the number of candidates in active clinical trials is small and product development challenges persist. Engagement with vaccine manufacturers has increased but is hampered by unclear demand and insufficient committed procurement. Investment in tuberculosis vaccine research and development therefore remains risky and inadequate. In parallel, more work is needed to identify and plan for cost-effective implementation while mitigating potential hesitancy and stigma to ensure uptake of new tuberculosis vaccines once licensed. Increased diversification of funders and strategic coordination of multiple stakeholders is needed more than ever.
引用
- van Riet E, Corleis B, Giersing BK, et al. Accelerating research and development of new vaccines against tuberculosis: 5-year progress on the global roadmap. Lancet Infect Dis. 2026. PMID: 41864213. doi:10.1016/S1473-3099(26)00019-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。